NewGenIvf Group Ltd NIVF
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $23.7M | $371.7K | $5.1M | $506.3K | $4.1M | — |
| Cost of revenue | $3.8M | $3.6M | $3.5M | $4.4M | $3.1M | — |
| Gross profit | $955.8K | $1.8M | $1.7M | $1.5M | $1.0M | — |
| SG&A | $10.5M | $2.8M | $1.6M | $1.1M | $801.3K | — |
| Total operating expenses | $11.7M | $3.0M | $1.6M | $1.1M | $826.0K | — |
| Operating income | -$10.7M | -$1.2M | $42.2K | $398.7K | $198.8K | — |
| Interest expense | — | $765.2K | — | — | — | — |
| Pre-tax income | $9.7M | -$960.8K | $108.4K | $344.0K | $156.2K | — |
| Income tax | — | $486.7K | — | $208.1K | $294.7K | — |
| Net income | $9.9M | -$524.6K | $130.2K | $458.7K | -$533 | — |
| EPS, basic | 1,932.59 | -39,678.88 | 117,173.70 | 4.72 | 0.00 | — |
| EPS, diluted | 27.36 | -39,678.88 | 117,173.70 | 4.72 | 0.00 | — |
| Shares, diluted (wtd. avg.) | 361,113 | 13 | 1 | 28,797 | 560,000 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $758.6K | $457.7K | $54.1K | $27.6K | $28.8K | $106.2K |
| Receivables | $166.5K | $49.2K | $9.4K | $13.0K | — | — |
| Inventory | $335.4K | $80.8K | $126.3K | $46.9K | — | — |
| Total current assets | $7.4M | $3.2M | $2.5M | $2.4M | — | — |
| Property, plant and equipment | $1.8M | $273.1K | $162.2K | $122.7K | — | — |
| Other intangibles | $21.4M | — | — | — | — | — |
| Total assets | $32.7M | $3.6M | $4.5M | $2.9M | — | — |
| Accounts payable | $779.3K | $1.3M | $172.6K | $104.7K | — | — |
| Total current liabilities | $2.4M | $2.7M | $1.1M | $2.6M | — | — |
| Total liabilities | $6.7M | $5.1M | $1.2M | $2.8M | — | — |
| Retained earnings | $8.9M | -$986.0K | -$461.4K | -$591.5K | — | — |
| Total equity | $26.6M | -$1.0M | $3.2M | $100.7K | -$914.9K | -$984.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.9M | -$8.3M | -$1.8M | $1.7M | $1.4M | — |
| Depreciation and amortisation | $188.1K | $19.5K | $31.2K | $100.5K | $166.7K | — |
| Stock-based compensation | — | — | — | $240.0K | $200.0K | — |
| Capital expenditure | $135.0K | $53.0K | $69.8K | $94.5K | $16.6K | — |
| Investing cash flow | -$7.6M | -$53.0K | -$69.8K | -$94.5K | -$16.6K | — |
| Financing cash flow | $19.0M | $8.7M | $1.9M | -$1.6M | -$1.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-096245.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $4.1M | $506.3K | $5.1M | $371.7K | $23.7M |
| Gross profit | — | $1.0M | $1.5M | $1.7M | $1.8M | $955.8K |
| Net income | — | -$533 | $458.7K | $130.2K | -$524.6K | $9.9M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.72B | 18.7x | 6.5% |
| SHC | Sotera Health Co | $5.17B | 67.0x | 5.7% |
| PGNY | Progyny, Inc. | $2.22B | 44.6x | 10.4% |
| AGL | agilon health, inc. | $1.51B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $373.3M | 26.5x | 20.5% |
| BRTX | BioRestorative Therapies, Inc. | $41.3M | — | -10.3% |
| CCEL | CRYO CELL INTERNATIONAL INC | $35.9M | — | -1.3% |
| MGRX | MANGOCEUTICALS, INC. | $5.0M | — | -26.0% |